Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Cancer. 2021 Feb 1;127(3):437-448. doi: 10.1002/cncr.33240. Epub 2020 Nov 2.
To the authors' knowledge, little is known regarding the association between recent oncologic treatment and mortality in patients with cancer who are infected with coronavirus disease 2019 (COVID-19). The objective of the current study was to determine whether recent oncologic treatment is associated with a higher risk of death among patients with carcinoma who are hospitalized with COVID-19.
Data regarding 248 consecutive patients with carcinoma who were hospitalized with COVID-19 were collected retrospectively from 33 hospitals in Hubei Province, China, from January 1, 2020, to March 25, 2020. The follow-up cutoff date was July 22, 2020. Univariable and multivariable logistic regression analyses were performed to identify variables associated with a higher risk of death.
Of the 248 patients enrolled, the median age was 63 years and 128 patients (52%) were male. On admission, 147 patients (59%) did not undergo recent oncologic treatment, whereas 32 patients (13%), 25 patients (10%), 12 patients (5%), and 10 patients (4%), respectively, underwent chemotherapy, surgery, targeted therapy, and radiotherapy. At the time of last follow-up, 51 patients (21%) were critically ill during hospitalization, 40 of whom had died. Compared with patients without receipt of recent oncologic treatment, the mortality rate of patients who recently received oncologic treatment was significantly higher (24.8% vs 10.2%; hazard ratio, 2.010 [95% CI, 1.079-3.747; P = .027]). After controlling for confounders, recent receipt of chemotherapy (odds ratio [OR], 7.495; 95% CI, 1.398-34.187 [P = .015]), surgery (OR, 8.239; 95% CI, 1.637-41.955 [P = .012]), and radiotherapy (OR, 15.213; 95% CI, 2.091-110.691 [P = .007]) were identified as independently associated with a higher risk of death.
The results of the current study demonstrated a possible association between recent receipt of oncologic treatment and a higher risk of death among patients with carcinoma who are hospitalized with COVID-19.
据作者所知，关于最近接受过肿瘤治疗的癌症患者在感染 2019 年冠状病毒病（COVID-19）后的死亡率，人们知之甚少。本研究的目的是确定最近接受过肿瘤治疗是否与因 COVID-19 住院的癌症患者的死亡风险增加有关。
回顾性收集了 2020 年 1 月 1 日至 3 月 25 日期间来自中国湖北省 33 家医院的 248 例连续癌症住院患者的数据。随访截止日期为 2020 年 7 月 22 日。采用单变量和多变量逻辑回归分析确定与死亡风险增加相关的变量。
在纳入的 248 例患者中，中位年龄为 63 岁，128 例（52%）为男性。入院时，147 例（59%）未接受近期肿瘤治疗，32 例（13%）、25 例（10%）、12 例（5%）和 10 例（4%）分别接受化疗、手术、靶向治疗和放疗。在最后一次随访时，51 例（21%）患者在住院期间病情危重，其中 40 例死亡。与未接受近期肿瘤治疗的患者相比，近期接受肿瘤治疗的患者死亡率明显更高（24.8% vs 10.2%；风险比，2.010 [95%CI，1.079-3.747；P=.027]）。在控制混杂因素后，近期接受化疗（比值比 [OR]，7.495；95%CI，1.398-34.187 [P=.015]）、手术（OR，8.239；95%CI，1.637-41.955 [P=.012]）和放疗（OR，15.213；95%CI，2.091-110.691 [P=.007]）被确定为与死亡风险增加独立相关。
本研究结果表明，最近接受肿瘤治疗与因 COVID-19 住院的癌症患者死亡风险增加之间可能存在关联。
